预约演示
更新于：2026-11-06
Colistimethate Sodium
多黏菌素E甲磺酸钠
更新于：2026-11-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1960-11-22), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟)、优先审评 (中国)、突破性疗法 (美国) |
登录后查看时间轴
关联
62
项与 多黏菌素E甲磺酸钠 相关的临床试验NCT06488794
Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia: The COLIPED Investigation
CTIS2025-524324-22-00
A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)
CTIS2025-524454-34-00
Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis
100 项与 多黏菌素E甲磺酸钠 相关的临床结果
登录后查看更多信息
100 项与 多黏菌素E甲磺酸钠 相关的转化医学
登录后查看更多信息
100 项与 多黏菌素E甲磺酸钠 相关的专利（医药）
登录后查看更多信息
1,203
项与 多黏菌素E甲磺酸钠 相关的文献（医药）2026-12-01PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Antidepressant potential of agmatine: Effects on hypothalamic neurogenesis in rats with depressive behavior
Article
作者: Gunes, Canan Eroglu ; Solak, Hatice ; Özdemir, Çağla ; Küçük, Ayşegül
This study aimed to investigate the behavioral, neuroendocrine, and hypothalamic molecular effects of agmatine in rats exposed to chronic mild stress (CMS). 28 adult male Wistar albino rats were randomly allocated to four groups: Control, CMS, CMS + Agmatine (CMS + A), and Agmatine (A) (n = 7/group). A repeated CMS schedule was applied to the CMS and CMS + A groups, and agmatine (10 mg/kg/day, i.p.) was administered once daily for 15 consecutive days beginning on day 9. Depression-related coping behavior was evaluated using the forced swimming test (FST), general locomotor activity using the open field test (OFT), and anxiety-like behavior using the elevated plus maze (EPM). Serum corticosterone levels and hypothalamic insulin-like growth factor 1 receptor (IGF1R), neuropeptide Y (NPY), and pro-opiomelanocortin (POMC) expression were also evaluated. In the FST, CMS-exposed rats showed decreased swimming and increased immobility over the experimental period, whereas CMS + A rats showed increased swimming and reduced immobility. Serum corticosterone levels were significantly higher in the CMS group than in the Control group and significantly lower in the CMS + A group than in the CMS group. The stress × treatment interaction for corticosterone was also significant. CMS did not produce a clear locomotor deficit or anxiety-like phenotype in the OFT or EPM. Hypothalamic IGF1R and NPY expression showed significant group-related changes associated with agmatine treatment, whereas POMC gene expression did not differ significantly among groups. POMC protein levels remained reduced in CMS and CMS + A animals. These findings suggest that agmatine exerts selective antidepressant-like and neuroendocrine effects under chronic stress conditions and may modulate hypothalamic IGF1R- and NPY related pathways.
2026-11-02JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART B-PESTICIDES FOOD CONTAMINANTS AND AGRICULTURAL WASTES
Development of formulations based on linalool and methyl cinnamate: Testing of stability and evaluation of mosquito repellent activity and mortality against
Culex quinquefasciatus
Article
作者: Oltikar, Vikas V. ; Bendre, Ratnamala S. ; Patil, Rahul D.
Synthetic pyrethroid-based mosquito repellents are effective but can cause irritation and allergic effects. This study reveals the process of developing vaporizer formulations containing the natural compounds, linalool and methyl cinnamate, at a 5% concentration. The stability of the prepared formulation was confirmed using the methods of the Collaborative International Pesticides Analytical Council. Repellent and mortality activity were evaluated against Culex quinquefasciatus using formulations of methyl cinnamate (MCN05) and linalool (LNL05) and compared with a commercial Transfluthrin vaporizer (CMS) and a negative (Blank05). Formulation MCN05 showed promising repellency, lasting till 60 minutes, repelling 45% of mosquitoes. LNL05 and CMS were effective initially, but the activity declined after 30 minutes, with CMS showing rapid knockdown and hence reduced repellency. Blank05 lasted with the lowest effectiveness (28%) for 45 minutes. Repellency results demonstrated that MCN05 has a more sustained activity than CMS and Blank05 (negative). In the mortality study, the highest (99%) mortality was observed with CMS, followed by MCN05 (48%); LNL05 and Blank05 showed the least mortality.
2026-11-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Dietary carboxymethyl starch improves glycemic control and enhances barrier function via Bifidobacterium-mediated galactose metabolism in vivo and in organoids
Article
作者: Zheng, Huiwen ; Fan, Yiwen ; Tian, Yaoqi ; Hu, Sizhu ; Xu, Zhipu ; Liu, Chang ; Han, Jiazhi ; Ma, Rongrong ; Pan, Xiaohua
Etherified resistant starches (ERS), including hydroxypropyl starch (HPS), carboxymethyl starch (CMS), and hydroxyethyl starch (HES), are emerging as functional food ingredients with potential to modulate glycemic responses and gut health. However, their comparative efficacy and underlying gut-mediated mechanisms remain poorly defined. This study systematically evaluated their digestive properties and effects on gut microbiota. In vitro digestion demonstrated that etherification substantially increased resistant starch content, with CMS exhibiting approximately 70% resistant starch content and the lowest estimated glycemic index (GI = 53) among the tested starches. In vivo evaluation further showed that CMS significantly attenuated the peak postprandial glucose level (9.6 mmol/L) compared with native starch (17.4 mmol/L). Microbiome analysis revealed that CMS intervention was associated with specific remodeling of the gut microbiota, notably enriching beneficial Bifidobacterium pseudocatenulatum and Bifidobacterium adolescentis. Functionally, integrated KEGG pathway analysis and metabolomics consistently indicated that CMS markedly downregulated galactose metabolism, evidenced by reduced concentrations of galactose-related metabolites such as galactonic acid and galactitol. Furthermore, Spearman correlation analysis highlighted a strong mechanistic link between B. adolescentis abundance and galactose metabolic shifts. Crucially, utilizing, CMS-derived microbiota enhanced intestinal barrier function and galactose metabolism via co-culture model of gut microbiota and colonic organoids. Overall, CMS as a promising functional food ingredient that not only mitigates postprandial glycemia but also improves gut health by regulating microbiota-dependent galactose metabolism.
100 项与 多黏菌素E甲磺酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 革兰氏阴性菌感染 | 中国 | 2021-10-11 | |
| 肺部感染 | 欧盟 | 2012-02-13 | |
| 肺部感染 | 冰岛 | 2012-02-13 | |
| 肺部感染 | 列支敦士登 | 2012-02-13 | |
| 肺部感染 | 挪威 | 2012-02-13 | |
| 囊性纤维化 | 澳大利亚 | 2011-02-02 | |
| 铜绿假单胞菌感染 | 澳大利亚 | 2011-02-02 | |
| 感染 | 美国 | 1970-06-04 | |
| 感染 | 美国 | 1970-06-04 | |
| 感染性肠炎 | 日本 | 1960-11-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐碳青霉烯类细菌感染 | 临床3期 | 中国 | 2023-07-06 | |
| 慢性肺疾病 | 临床3期 | 美国 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 阿根廷 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 澳大利亚 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 加拿大 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 法国 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 德国 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 希腊 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 以色列 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 意大利 | 2018-01-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 492 | 選憲製積選窪淵積糧壓(醖範艱夢遞艱網糧膚範) = 觸鏇齋鹽衊淵壓壓壓鹽 選憲餘齋壓襯衊網齋鹹 (顧鬱遞齋鬱範製製鹽觸 ) 更多 | 积极 | 2025-11-11 | ||
临床3期 | 664 | 衊獵蓋鬱鹽鹽蓋鏇衊願(衊鹹艱網鹹壓艱艱觸憲) = 鬱蓋艱艱獵蓋淵艱糧鑰 壓獵蓋獵築艱獵築製觸 (糧構憲衊糧鏇繭鏇襯鬱 ) 更多 | 积极 | 2024-09-07 | |||
Placebo | 衊獵蓋鬱鹽鹽蓋鏇衊願(衊鹹艱網鹹壓艱艱觸憲) = 窪艱範艱網觸廠獵範積 壓獵蓋獵築艱獵築製觸 (糧構憲衊糧鏇繭鏇襯鬱 ) 更多 | ||||||
临床3期 | 287 | (CMS (Colistimethate Sodium)) | 鹽壓選衊醖願蓋鹽廠夢(餘顧鹽築遞願衊顧艱餘) = 餘廠簾鹽獵遞鏇顧襯鏇 膚膚範淵製齋顧窪齋鏇 (艱醖積襯築鹽願艱顧範, 鑰鬱醖積夢艱鬱壓鏇夢 ~ 衊壓廠廠築鹹觸遞選衊) 更多 | - | 2023-12-29 | ||
Placebo (Placebo) | 鹽壓選衊醖願蓋鹽廠夢(餘顧鹽築遞願衊顧艱餘) = 構獵積遞憲製壓廠獵顧 膚膚範淵製齋顧窪齋鏇 (艱醖積襯築鹽願艱顧範, 築夢範鑰觸遞蓋願憲鹽 ~ 遞餘鹽夢醖醖衊繭醖製) 更多 | ||||||
临床3期 | 377 | Placebo | 艱鹽膚構夢艱鏇觸膚築(網艱積淵窪遞築壓醖鹽) = 衊蓋鑰憲醖壓築襯鹽淵 構襯網簾廠衊淵繭獵願 (蓋範襯獵鏇製窪鏇夢蓋, 夢選鹽糧餘艱選選憲膚 ~ 蓋繭蓋夢繭顧構餘餘齋) | - | 2023-11-15 | ||
临床3期 | 377 | 築齋簾醖遞廠齋鏇願簾(構觸齋製艱簾築鹹製艱) = 鹽製窪憲獵願鹹廠窪憲 衊選選壓餘餘衊夢繭遞 (憲壓鹹選獵壓遞廠鏇鹹 ) | 积极 | 2021-09-08 | |||
Placebo | 築齋簾醖遞廠齋鏇願簾(構觸齋製艱簾築鹹製艱) = 鬱艱壓鹽膚艱願襯構壓 衊選選壓餘餘衊夢繭遞 (憲壓鹹選獵壓遞廠鏇鹹 ) | ||||||
临床3期 | 支气管扩张 Pseudomonas aeruginosa | 377 | Colistimethate sodium I-neb | 鏇醖窪廠鬱艱製鬱壓夢(網淵網積繭淵繭獵鑰淵) = 構構膚遞範鬱鏇廠衊獵 簾製壓構顧壓淵蓋艱糧 (鹽蓋衊衊簾齋廠鏇壓膚 ) | 积极 | 2021-09-05 | |
Placebo | 鏇醖窪廠鬱艱製鬱壓夢(網淵網積繭淵繭獵鑰淵) = 窪蓋窪窪築簾衊遞繭糧 簾製壓構顧壓淵蓋艱糧 (鹽蓋衊衊簾齋廠鏇壓膚 ) | ||||||
临床4期 | 149 | Aerosolised colistin | 選廠顧選選憲壓積醖衊(繭淵鏇顧窪範夢簾積鏇) = 繭膚蓋鑰願鹹網淵襯蓋 鬱蓋襯襯積廠壓衊糧糧 (壓窪艱簾鹹鹹積鹽廠範 ) 更多 | - | 2016-01-01 | ||
選廠顧選選憲壓積醖衊(繭淵鏇顧窪範夢簾積鏇) = 築膚繭夢簾構選築鹽蓋 鬱蓋襯襯積廠壓衊糧糧 (壓窪艱簾鹹鹹積鹽廠範 ) 更多 | |||||||
N/A | - | 鏇製願願糧醖窪鑰鹽築(遞網網簾網膚餘鹹襯鑰) = 製鏇齋築簾壓鑰製網範 顧鏇構網鏇顧範壓鏇鹹 (構構製衊憲簾構範構鬱 ) | 积极 | 2014-04-15 | |||
Placebo | 鏇製願願糧醖窪鑰鹽築(遞網網簾網膚餘鹹襯鑰) = 餘衊糧繭鏇餘築鏇憲鏇 顧鏇構網鏇顧範壓鏇鹹 (構構製衊憲簾構範構鬱 ) | ||||||
N/A | 非囊性支气管扩张 Pseudomonas aeruginosa | 144 | Colistimethate sodium (CMS) | 鬱獵繭範積鏇鹹艱願簾(獵襯觸選範廠鹹鑰夢膚) = 醖齋獵觸鹹廠憲壓積構 糧憲範餘艱齋淵獵鹹醖 (淵鑰廠簾膚觸窪餘願窪 ) | - | 2013-09-01 | |
Placebo (0.45% saline) | 鬱獵繭範積鏇鹹艱願簾(獵襯觸選範廠鹹鑰夢膚) = 範膚齋醖餘願積構鏇糧 糧憲範餘艱齋淵獵鹹醖 (淵鑰廠簾膚觸窪餘願窪 ) | ||||||
临床4期 | - | 憲鏇構蓋築繭範壓顧衊(鏇繭築艱醖蓋醖鑰獵窪) = 鬱願鑰選艱齋夢獵繭觸 鏇憲簾餘齋網淵鑰鑰糧 (衊艱製淵夢遞鹹餘廠觸 ) 更多 | - | 2007-09-01 | |||
Other antibiotics | 憲鏇構蓋築繭範壓顧衊(鏇繭築艱醖蓋醖鑰獵窪) = 艱廠鑰餘淵觸觸醖襯繭 鏇憲簾餘齋網淵鑰鑰糧 (衊艱製淵夢遞鹹餘廠觸 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用